RxDoctor Payments DataLook up a doctor →

Justin Lande

Internal Medicine · Danville, KYNPI 1538542378

Payments from drug & device makers

$59,577in general payments, 2019–2025

Across 815 payments — averaging $73.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$48K
  • Eli Lilly$2K
  • Novo Nordisk$2K
  • AbbVie$1K
  • GSK$1K
  • Pfizer$561
  • plus $5K from 46 others

What the payments were for

  • Consulting fees$1,9503%
  • Speaking & faculty fees$45,30076%
  • Travel & lodging$1,6033%
  • Food & beverage$10,71918%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,577 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$5,184
Medicare patients
210
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide517$674,086
MounjaroTirzepatide262$358,176
JardianceEmpagliflozin275$330,886
TrulicityDulaglutide155$257,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter157$167,642
Repatha SureclickEvolocumab149$143,816
EliquisApixaban148$143,613
Tresiba Flextouch U-100Insulin Degludec81$68,054
VraylarCariprazine Hcl48$65,557
LinzessLinaclotide53$52,741
XareltoRivaroxaban45$48,995
JanuviaSitagliptin Phosphate40$45,499
FarxigaDapagliflozin Propanediol40$45,182
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$32,220
ProliaDenosumab15$25,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,510$674,086517 claims
Lilly USA, LLCMounjaro, Trulicity$48,274$615,468417 claims
Boehringer IngelheimJardiance$316$330,886275 claims
GSKTrelegy Ellipta, Breo Ellipta$1,060$184,398196 claims
PfizerEliquis$561$143,613148 claims
AbbVieVraylar, Linzess, Qulipta$1,193$139,851122 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Airsupra$548$101,489121 claims
MerckJanuvia, Janumet, Dulera$377$64,13770 claims
Johnson & JohnsonXarelto$148$48,99545 claims
AmgenProlia$552$25,56815 claims
NovartisEntresto$469$21,04920 claims
Astellas Pharma US IncMyrbetriq$157$20,88737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →